Clinical Study on the Amelioration of Endocrine and Metabolic Abnormalities in Patients with PCOS through Oral Administration of Lycium barbarum Glycopeptide

INTERVENTION: Intervention group:Oral Lycium Barbarum Polypeptide;Control group:placebo; CONDITION: Polycystic ovary syndrome PRIMARY OUTCOME: Serum Androgens (Total Testosterone, Dehydroepiandrosterone, Sex Hormone‐Binding Globulin);Inflammatory markers (IL‐6, TNF‐a) and ultrasound‐measured follicular count/ovarian volume.; SECONDARY OUTCOME: Glucose metabolism: fasting blood glucose, insulin, HOMA‐IR;; Lipid metabolism: TG, LDL‐C, HDL‐C;Gut Microbiota Diversity (16S rRNA Sequencing);Menstrual Cycle Recovery Rate and Acne/Hirsutism Score (Ferriman‐Gallwey); INCLUSION CRITERIA: 1. The age of all patients was <= 40 years old. 2. Patients in the PCOS group. They were included based on the Rotterdam diagnostic criteria in 2003 [5], and were diagnosed with PCOS if they met two or more of the following three conditions (excluding other conditions that cause hyperandrogenemia): (1) Infrequent ovulation or no ovulation; (2) Clinical or biochemical examination suggesting hyperandrogenemia; (3) Ultrasound examination showing polycystic changes in the ovary: at least one ovary had >= 12 small follicles with a diameter of 2‐9 mm, and/or the volume of the ovary was > 10 cm^3. 3. Signed informed consent form.